Rocket Pharmaceuticals updates RP-A501 Danon disease trial data
Tweet Send to a Friend
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) released updated clinical findings for its gene therapy candidate RP-A501, targeting Danon disease, following an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




